Target intelligence / Profile preview

Family with sequence similarity 13 member A (FAM13A)

Target
FAM13A
Molecular classification
Rho GTPase-activating protein (contains a RhoGAP domain), Intracellular signaling modulator, Other (not a receptor, enzyme, channel, or transporter)
01

Overview

Family with sequence similarity 13 member A (FAM13A) is a cytoplasmic and nuclear protein characterized by an N-terminal Rho GTPase-activating protein (RhoGAP) domain and C-terminal coiled-coil domains. It regulates RhoA GTPase activity and modulates actin cytoskeleton dynamics, contributing to processes such as cilia movement, cellular remodeling, and epithelial-mesenchymal transition. FAM13A also influences Wnt/β-catenin signaling by recruiting and modulating components of the β-catenin destruction complex. Genome-wide association studies have linked genetic variants in FAM13A to reduced lung function and higher risk for chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, asthma, and lung cancer. It also acts as a modifier gene in cystic fibrosis and has been implicated in insulin sensitivity and adipose tissue biology. FAM13A is regulated through Akt- and PP2A-mediated phosphorylation, which controls its nuclear-cytoplasmic distribution. There are currently no drugs that directly target FAM13A, and no direct safety issues are known for its modulation.

Other names
FAM13AKIAA0914ARHGAP48FAM13A1Protein FAM13Afamily with sequence similarity 13, member A1FAM13A1_v2 protein
02

Mechanism of action

Not applicable; no drugs directly target FAM13A as of the current literature

03

Biological functions

Regulation of RhoA GTPase activityModulation of actin cytoskeleton and cilia movementSignal transduction via the Wnt/β-catenin pathwayRegulation of nuclear-cytoplasmic shuttlingRegulation of adipocyte function and lipolysis
04

Disease associations

Chronic obstructive pulmonary disease (COPD)Pulmonary fibrosisLung cancerAsthmaCystic fibrosis (modifier gene)Metabolic disease/insulin resistance
05

Safety considerations

Not established for pharmacological modulation; knockout mice are viable and healthy, suggesting limited essential function in development
06

Biomarkers

Lung function/decline risk in COPD (genetic biomarker)Disease susceptibility marker in pulmonary fibrosis, asthma, lung cancer (genetic association marker)Insulin sensitivity (marker gene in metabolic studies)

Beyond the preview

Go deeper on Family with sequence similarity 13 member A (FAM13A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Family with sequence similarity 13 member A (FAM13A).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call